ChemAxon said this week that Boehringer Ingelheim will use its cheminformatics platform to store, search, and visualize chemical entities, properties, and reactions as part of its internal and external drug research and development efforts.

ChemAxon said that Boehringer chose its software after evaluating factors such as its return on investment, performance, robustness, and scalability.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.